{"symbol":"ABBV","fiscalQuarter":"Q2-2017","reportDate":"2017-07-28","reportTime":"BMO","status":"reported","company":{"name":"AbbVie Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/ABBV/earnings/Q2-2017","postBrief":{"headline":"AbbVie Beats on EPS, Stock Down 1.8%","keyNumbers":[{"metric":"EPS","actual":"$1.42","expected":"N/A","surprise":"+0.06%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management expressed confidence in the pipeline but did not provide specific guidance.","They highlighted ongoing investments in research and development."],"summary":"Overall, management conveyed a positive outlook on their product pipeline. However, the lack of specific guidance may have left some investors uncertain."},"guidanceChanges":{"summary":"No guidance was provided during the earnings call.","changes":[]},"whatItMeans":"AbbVie's earnings report showed a slight beat on EPS, which is a positive sign for the company. However, the stock fell by 1.8% likely due to the absence of revenue details and future guidance. Investors may be cautious as they await more information on the company's performance and strategy moving forward.","metaDescription":"AbbVie Inc (ABBV) Q2 2017 earnings: EPS beat by 0.06%. Stock down 1.8%. Full breakdown."}}